Table S1: TsZM-bl assay pseudovirus neutralization by plasma from all adjuvant groups.

adjuvant group / animal number	time point	B clade tier 1		tier 2	C clade tier 2		CRF01_AE tier 2
		BaL.26	Bx08.16	PVO.4	DU123.6	DU172.17	93TH976.1
group 1 (STS)							
4828	w0	<20*	<20	<20	<20	<20	<20
	w23	**55**	**65**	<20	21	26	26
	w32	26	**45**	<20	25	26	23
4829	w0	<20	<20	<20	<20	<20	<20
	w23	**47**	**60**	<20	<20	<20	<20
	w32	36	**50**	<20	<20	<20	<20
4844	w0	<20	<20	<20	<20	<20	<20
	w23	32	**53**	<20	<20	<20	<20
	w32	38	**66**	<20	23	30	<20
group 2 (STS+LA)							
4830	w0	<20	22	<20	<20	<20	<20
	w23	**72**	**98**	<20	<20	<20	<20
	w32	**56**	**100**	<20	23	21	<20
4831	w0	<20	<20	<20	<20	<20	<20
	w23	**64**	**81**	<20	<20	21	22
	w32	**60**	**79**	<20	26	23	23
4845	w0	<20	25	<20	<20	21	<20
	w23	**69**	**104**	<20	24	36	22
	w32	37	**72**	<20	<20	<20	<20
group 3 (STS+LA+oCpG)							
4838	w0	<20	<20	<20	<20	23	<20
	w23	**99**	**103**	<20	27	36	28
	w32	**71**	**96**	<20	25	35	<20
4839	w0	<20	<20	<20	20	<20	22
	w23	**170**	**141**	<20	<20	<20	<20
	w32	**170**	**133**	<20	20	<20	<20
4840	w0	<20	<20	<20	<20	<20	<20
	w23	**97**	**96**	<20	<20	<20	<20
	w32	**83**	**89**	<20	<20	24	<20
group 4 (STS+LA+R848)							
4836	w0	20	25	<20	<20	<20	<20
	w23	**163**	**129**	<20	<20	<20	<20
	w32	**89**	**98**	<20	34	30	22
4837	w0	<20	36	<20	<20	<20	<20
	w23	**138**	**198**	<20	<20	<20	<20
	w32	**67**	**140**	<20	<20	23	<20
4848	w0	<20	<20	<20	<20	<20	<20
	w23	**49**	**46**	<20	<20	<20	<20
	w32	**40**	**44**	<20	<20	<20	<20
group 5 (STS+oCpG)							
4834	w0	<20	22	<20	<20	<20	<20
	w23	**139**	**135**	<20	<20	25	<20
	w32	**74**	**96**	<20	23	22	21
4835	w0	<20	22	<20	<20	<20	<20
	w23	**93**	**86**	<20	<20	<20	<20
	w32	**61**	**67**	<20	<20	<20	<20
4847	w0	<20	23	<20	<20	<20	<20
	w23	**58**	**242**	<20	<20	<20	<20
	w32	**50**	**119**	<20	26	21	<20
group 6 (STS+R848)							
4832	w0	<20	25	<20	<20	<20	<20
	w23	**201**	**272**	<20	21	<20	26
	w32	**100**	**170**	<20	21	<20	25
4833	w0	<20	<20	<20	<20	<20	<20
	w23	**143**	**118**	<20	<20	23	<20
	w32	**69**	**91**	<20	22	<20	<20
4846	w0	<20	23	<20	<20	<20	<20
	w23	**107**	**161**	<20	32	<20	<20
	w32	**129**	**142**	<20	24	22	<20
group 7 (STS+oCpG+R848)							
4841	w0	<20	<20	<20	<20	21	<20
	w23	**827**	**380**	<20	26	26	31
	w32	**716**	**276**	<20	**48**	30	23
4842	w0	<20	<20	<20	24	<20	<20
	w23	**173***	**114**	<20	27	27	24
	w32	**134**	**181**	<20	34	22	<20
4843	w0	<20	<20	<20	<20	<20	<20
	w23	**121**	**155**	<20	<20	<20	22
	w32	**128**	**145**	<20	26	<20	<20

* Plasma dilution resulting in 50% reduction of infection.

Figure S1

Supplemental Figure S1. ELISA binding data for antibodies elicited by gp140 B.63521 in oil-in-water emulsions.

ELISA data underlying the endpoint titer results shown in Fig. 2 are plotted. Adjuvant mixtures are constant across each row, each column represents an assayed time point. In each row, solid lines, dashed lines, and dotted lines represent individual animals.

Figure S2

Supplemental Figure S2. ADCC data for antibodies elicited by gp140 B.63521 in oil-in-water emulsions.

ADCC data underlying the results shown in Fig. 6 are plotted. Adjuvant mixtures are constant across each row, each column represents an assayed time point. In each row, solid lines, dashed lines, and dotted lines represent individual animals. Data on the left in the first three columns are for B.BaL-coated target cells and underly the data shown in Fig. 6. Data on the right in the final three columns are for chronically infected target cells (A1953).